A total of 37 % and 47 % of verteporfin-treated patients versus 45 % and 53 % of placebo recipients lost > or = 15 letters of VA at month 12 and month 24 , respectively ; 16 % and 23 % of verteporfin-treated patients versus 17 % and 25 % of placebo recipients lost > or = 30 letters at month 12 and month 24 , respectively .
